logo-loader

Race Oncology Ltd to reveal new agreement

Published: 10:00 07 Jul 2017 AEST

shutterstock_578045545_595edbdecc60d
The company has a focus in the field of cancer

Race Oncology Ltd (ASX:RAC) has been granted a trading halt by the ASX, pending details of a joint venture.

The company recently secured an agreement with the National Cancer Institute (NCI) in the United States.

The halt will remain in place until the opening of trade on Tuesday 11th July 2017, or earlier if an announcement is made to the market.

Race Oncology looks to accelerate clinical development of bisantrene

Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Daniel Tillett joins Jonathan Jackson in the Proactive studio to provide an update on the company’s movements over the last few months. Just recently, Race received a $4 million R&D tax incentive tto accelerate clinical development of bisantrene,...

1 month, 1 day ago